|
Match
|
Document |
Document Title |
|
|
7618988 |
Use of substituted aminomethyl chromans
Compounds of formula I in which R has a meaning as indicated in claim 1 , or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement...
|
|
|
7615535 |
Inhibiting GS-FDH to modulate no bioactivity
Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of...
|
|
|
7601354 |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for...
|
|
|
7598290 |
Cytotoxic agents comprising new C-2 modified taxanes
The invention relates to taxanes and to novel cytotoxic agents comprising taxanes and their therapeutic use as a result of delivering the taxanes to a specific cell population in a targeted fashion...
|
|
|
7595347 |
Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
Pre-treatment with α,β unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone...
|
|
|
7589111 |
C10 cyclopentyl ester substituted taxanes
A taxane having a cyclopentyl ester substituent at C10, a keto substituent at C9, a hydroxy substituent at C2, a 2-thienyl substituent at C3′ and an isopropoxycarbamate substituent at C3′.
|
|
|
7585893 |
Anti-cancer composition comprising DMXAA or related compound
The present invention relates to the use of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for the treatment of cancer, wherein...
|
|
|
7585889 |
Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension
Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The...
|
|
|
7585857 |
Cytotoxic agents comprising taxanes and their therapeutic use
A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more...
|
|
|
RE40839 |
Taxol treatment of cancer
The present invention is a method of treatment for a patient with cancer. In particular, it is a method of treating patients having lymphomas and breast cancer using the microtubule agent,...
|
|
|
7550609 |
Cytotoxic agents comprising taxanes and their therapeutic use
A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more...
|
|
|
7550466 |
Alpha and/or β-adrenergic antagonists and agonists to treat pain
The present disclosure provides for improved methods for treating pain, including pain associated with chronic inflammatory diseases, neuropathic pain and cancer by using α-adrenergic antagonists...
|
|
|
7528168 |
Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases
The invention relates to a method of preventing and/or treating a chronic and/or an atopic skin disease by administering an inhibitor of fatty acid oxidation to a patient in a pharmacologically...
|
|
|
7507817 |
Prostaglandin prodrugs
Novel compounds, and therapeutic methods, compositions and medicament related thereto are disclosed herein.
|
|
|
7504425 |
Compounds useful in the treatment of anthrax and inhibiting lethal factor
This invention relates to compounds of formula (I), and a method for treating anthrax or inhibiting lethal factor by administrating a composition containing a compound of formula (I) and a...
|
|
|
7501455 |
Pharmaceutical compositions containing plasma protein
The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance...
|
|
|
7495111 |
Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists
3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT 1A receptor (agonizing or...
|
|
|
7485320 |
Liposome for incorporating large amounts of hydrophobic substances
A liposome formulation for stably incorporating high content of hydrophobic substance is disclosed. The liposome includes two phospholipids with different phase transition temperatures such as...
|
|
|
7468437 |
Phenyl pyrrolidine ether tachykinin receptor antagonists
The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular...
|
|
|
7465754 |
Method of potentiating chemotherapy and treating solid tumors
This invention provides a method of treating solid tumors which comprises administering an effective amount of a combination of (1) a bioresponse modifier and (2) a chemotherapeutic agent. This...
|
|
|
7446126 |
Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
A process is provided for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel (I)
a synthon useful for the preparation of taxanes with antitumour activity, and intermediates for the...
|
|
|
7438900 |
Dendritic encapsulation of active agents
A pharmaceutical composition comprising an active agent bound to a scaffold for dendritic encapsulation wherein said scaffold is covalently or non-covalently attached to a polysaccharide. More...
|
|
|
RE40493 |
Porous paclitaxel matrices and methods of manufacture thereof
Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process...
|
|
|
7419998 |
Therapeutic methods and compositions involving isoflavones
Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R 1 is H, or R A CO where R A is...
|
|
|
7399783 |
Methods for the treatment of scar tissue
A topical composition and method for the reduction of scar tissue and/or improving the appearance of scar tissue after it has formed. The topical composition includes one or more flavonoids...
|
|
|
7390505 |
Nanoparticulate topiramate formulations
The present invention is directed to nanoparticulate compositions comprising topiramate. The topiramate particles of the composition have an effective average particle size of less than about 2...
|
|
|
7384977 |
Water soluble paclitaxel prodrugs
Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or...
|
|
|
7378399 |
Avermectins substituted in the 4″ and 4′-positions having pesticidal properties
What is described are a compound of the formula (I) Wherein A-B is —CH═CH— or —CH 2 —CH 2 —; n is 0 or 1; R 1 , is C 1 -C 12 alkyl, C 3 -C 8 cycloalkyl or C 2 -C 12 alkenyl; R 2 and R...
|
|
|
7371747 |
Cyanoalkylamino derivatives as protease inhibitors
The present invention is directed to novel cyanoalkylamino derivatives that are inhibitors of cysteine protease such as cathepsins K, S, B and L, in particular cathepsin K Pharmaceutical...
|
|
|
7368473 |
Paclitaxel enhancer compounds
One embodiment of the present invention is a compound represented by the Structural Formula (I):
Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In...
|
|
|
7361683 |
Paclitaxel aqueous injection solution and methods for preparing the same
The present invention provides an injectable pharmaceutical composition containing, as an active ingredient, paclitaxel, an anti-cancer agent. The injectable pharmaceutical composition comprises an...
|
|
|
7358275 |
Internal 1,15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension
Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The...
|
|
|
7357942 |
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are...
|
|
|
7354928 |
Small molecule inhibitors targeted at Bcl-2
The present invention relates to small molecule antagonists of Bcl-2 family proteins such as Bcl-2 and/or Bcl-X L . In particular, the present invention provides non-peptide cell permeable small...
|
|
|
7345088 |
Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
A pharmaceutical composition for treatment of malignancies, in particular a malignant disease which is associated with the development of bone metastases or excessive bone resorption, comprises in...
|
|
|
7342018 |
Urokinase inhibitors and uses thereof
The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.
|
|
|
7329634 |
3-Phenyl substituted 3-substituted-4ketolactams and ketolactones
The invention relates to novel 3-phenyl-substituted, 3-substituted 4-ketolactams and -lactones of the formula (I)
in which Q, W, X, Y, A, B and G are as defined in the disclosure, to...
|
|
|
7326421 |
Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues
An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of...
|
|
|
7314637 |
Method of administering liposomal encapsulated taxane
Liposomal-encapsulated taxane or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer. The liposomal...
|
|
|
7312240 |
Conformationally constrained paclitaxel analogs and their use as anticancer and anti-Alzheimers agents
Constrained paclitaxel derivatives include a bridge extending from the C-3′ phenyl to either the C4 or -3 positions. Many of the constrained paclitaxel derivatives provide activity comparable or...
|
|
|
7276228 |
Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase
Methods are provided for treating hematological disorders by inhibition of DNA hypomethylation and histone deacetylase. Such disorders include, for example, acute promyelocytic leukemia, acute...
|
|
|
7256213 |
Taxanes having a C10 carbonate substituent
Taxanes having a methylcarbonate or ethylcarbonate substituent at C(10), a hydroxy substituent at C(7), and a range of C(13) side chain substituents.
|
|
|
7250157 |
Dermatological compositions and methods
Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin...
|
|
|
RE39723 |
Semi-synthetic taxanes with antitumor and antiangiogenetic activities
Seco-baccatin III derivatives of formula:
wherein R, R 1 -R 4 , R 1 R′ , R 11 R″ , and R 111 R′″ are disclosed herein; pharmaceutical compositions comprising seco-baccatin...
|
|
|
7235583 |
Fatty acid-anticancer conjugates and uses thereof
The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates also are provided.
|
|
|
7232811 |
Furosemide modulators of HM74
Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:
|
|
|
7230013 |
C10 carbamoyloxy substituted taxane compositions
Compositions comprising a taxane having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.
|
|
|
7226944 |
Taxanes having a C7 carbonate substituent
Taxanes having a carbonate substituent at C(7), a hydroxy substituent at C(10), and a range of C(2), C(9), C(14), and side chain substituents.
|
|
|
7217770 |
Stable polymeric micelle-type drug composition and method for the preparation thereof
A biocompatible stable composition containing a hydrophobic drug, such as paclitaxel. The composition, which forms a syringeable polymeric micellar solution in aqueous or body fluids, is a...
|
|
|
7214701 |
Active substance combinations having insecticidal and acaricdal properties
The invention relates to insecticidal mixtures for protecting plants against attack by pests comprising
(a) compounds of the formula (I)
in which W, X, Y, Z, A, B, D and G...
|